Equities Analysts Issue Forecasts for IKT Q2 Earnings

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) – Investment analysts at HC Wainwright lifted their Q2 2026 EPS estimates for Inhibikase Therapeutics in a research note issued on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.10) per share for the quarter, up from their previous forecast of ($0.11). The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.42) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.11) EPS and FY2027 earnings at ($0.48) EPS.

Several other research analysts have also recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Tuesday, April 21st. Lifesci Capital raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a report on Monday, February 23rd. Finally, LADENBURG THALM/SH SH started coverage on shares of Inhibikase Therapeutics in a report on Wednesday, March 4th. They set a “buy” rating and a $4.00 price objective for the company. Four analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $5.50.

Inhibikase Therapeutics Price Performance

IKT opened at $1.70 on Thursday. The firm has a 50 day moving average price of $1.78 and a 200-day moving average price of $1.74. Inhibikase Therapeutics has a twelve month low of $1.33 and a twelve month high of $2.26. The stock has a market capitalization of $224.45 million, a price-to-earnings ratio of -3.95 and a beta of 0.96.

Inhibikase Therapeutics (NASDAQ:IKT) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10).

Hedge Funds Weigh In On Inhibikase Therapeutics

Hedge funds have recently modified their holdings of the company. The Manufacturers Life Insurance Company bought a new position in shares of Inhibikase Therapeutics in the first quarter worth approximately $48,000. SummitTX Capital L.P. purchased a new position in shares of Inhibikase Therapeutics in the first quarter worth $2,561,000. Kalehua Capital Management LLC lifted its holdings in shares of Inhibikase Therapeutics by 118.4% in the first quarter. Kalehua Capital Management LLC now owns 3,821,890 shares of the company’s stock worth $6,421,000 after buying an additional 2,071,890 shares in the last quarter. Rangeley Capital LLC purchased a new position in shares of Inhibikase Therapeutics in the first quarter worth $370,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Inhibikase Therapeutics in the first quarter worth $28,000. 3.81% of the stock is currently owned by institutional investors.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.